New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
07:55 EDTESRX, CVS, CTRXLeerink a buyer of Catamaran ahead of Q2 results
Leerink says it's a buyer of Catamaran (CTRX) ahead of the company's Q2 results as it believes shares have more room to run. The firm is cautious on Express Scripts (ESRX) after hearing from a specialist that service challenges may impact the company's 2015 and 2016 selling seasons. The firm remains positive on CVS Caremark (CVS), but notes shares have outperformed and the company could see retail pressure from recent drug inflation trends.
News For CTRX;ESRX;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
16:39 EDTESRXBerkshire Hathaway gives quarterly update on stakes
Subscribe for More Information
14:53 EDTCVS, ESRXCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
November 12, 2014
08:02 EDTCTRXCredit Suisse to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use